The first patents for Emend (aprepitant) have expired; however, there are no generic versions being made at this time. It is possible that the brand-name drug is protected by other patents or exclusivity rights and that a generic version will be introduced once they expire.
Emend® (aprepitant) is a prescription medication used for the prevention of nausea and vomiting caused by chemotherapy or surgery.
Emend is made by Merck & Co., Inc. Although the first patents for Emend have expired, the drug is not yet available in generic form.
The first patents for Emend expired in January 2011, June 2012, September 2012, and July 2013. However, generic versions are not yet available. This strongly suggests that other patents or exclusivity rights are still providing significant protection against generic competition.
The next patent set to expire will do so in April 2015. This is the earliest predictable date that a generic version of Emend could become available. However, there are other circumstances that could come up to extend or shorten the exclusivity period of Emend. This could include such things as other patents for specific Emend uses or lawsuits. Once Emend goes off patent, other companies may begin manufacturing a generic Emend drug.
Emend is a very expensive medication (as are many new nausea and vomiting medications). If you do not have insurance coverage (or if your insurance does not cover Emend) and you cannot afford Emend, you may qualify to receive free Emend from Merck. Ask your healthcare provider about the Emend patient assistance program.